Bookbuilding IPO | ₹29 Cr | Listed at BSE SME | Fri, Mar 20, 2026 - Tue, Mar 24, 2026
Speciality Medicines IPO is a book build issue of ₹29.14 crores. The issue is entirely a fresh issue of 0.24 crore shares of ₹29.14 crore.
Speciality Medicines IPO bidding started from Mar 20, 2026 and ended on Mar 24, 2026. The allotment for Speciality Medicines IPO was finalized on Mar 25, 2026. Speciality Medicines IPO will list on the BSE SME on Mar 30, 2026.
Speciality Medicines IPO is set final issue price at ₹124 per share. The lot size for an application is 1,000 shares. The minimum amount of investment required by an individual investor (retail) is ₹2,48,000 (2,000 shares) (based on upper price). The minimum lot size for investment in HNI is 3 lots (3,000 shares), amounting to ₹3,72,000.
Unistone Capital Pvt.Ltd. is the book running lead manager and Skyline Financial Services Pvt.Ltd. is the registrar of the issue. The Market Maker of the company is Aikyam Capital Private Limited.
Refer to Speciality Medicines IPO RHP for detailed Information.
IPO Open
Fri, Mar 20, 2026
IPO Close
Tue, Mar 24, 2026
Issue Price
₹124 per share
Market Cap (Pre-IPO)
₹108.94 Cr
| IPO Date | 20 to 24 Mar, 2026 |
| Listed on | Mon, Mar 30, 2026 |
| Face Value | ₹10 per share |
| Price Band | ₹117 to ₹124 |
| Issue Price | ₹124 per share |
| Lot Size | 1,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 23,50,000 shares (agg. up to ₹29 Cr) |
| Reserved for Market Maker | 1,50,000 shares Aikyam Capital Private Limited (agg. up to ₹2 Cr) |
| Fresh Issue (Ex Market Maker) | 22,00,000 shares (agg. up to ₹27 Cr) |
| Net Offered to Public | 22,00,000 shares (agg. up to ₹27 Cr) |
| Share Holding Pre Issue | 64,35,796 shares |
| Share Holding Post Issue | 87,85,796 shares |
| BSE Script Code | 544738 |
| ISIN | INE0R0M01014 |
Speciality Medicines IPO comprises a total issue size of 23,50,000 shares. The net offer to the public is 22,00,000 shares, after excluding 1,50,000 shares allotted on a firm basis. Of the Net offer 21,000 (0.95%) are allocated to QIB, 10,89,000 (49.50%) allocated to NII 10,90,000 (49.55%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
|---|---|---|---|
| QIB Shares Offered | 21,000 | 0.95% | 0.89% |
| NII (HNI) Shares Offered | 10,89,000 | 49.50% | 46.34% |
| − bNII > ₹10L | 7,26,000 | 30.89% | |
| − sNII < ₹10L | 3,63,000 | 15.45% | |
| Retail Shares Offered | 10,90,000 | 49.55% | 46.38% |
| Firm Reservations | |||
| Market Maker Shares Offered | 1,50,000 | 6.38% | |
| Total Shares Offered | 23,50,000 | 100.00% | 100.00% |
Investors can bid for a minimum of 2,000 shares and in multiples of 1,000 shares thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 2,000 | ₹2,48,000 |
| Individual investors (Retail) (Max) | 2 | 2,000 | ₹2,48,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,72,000 |
| S-HNI (Max) | 8 | 8,000 | ₹9,92,000 |
| B-HNI (Min) | 9 | 9,000 | ₹11,16,000 |
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets.
The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations products, which are available in various dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions.
The company operates via two models: (a) contract manufacturing of finished formulations for international distribution, and (b) marketing and distribution of sourced specialty pharmaceutical products.
The company has expanded internationally with registered or pending products in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia. Its distribution network builds strong relationships across over 20 states in India and more than 35 countries worldwide world.
As of Feb 28, 2026, the company has 7 products registered overseas and 54 products are in the registration process across 5 countries.
Competitive Strengths
| Period Ended | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Assets | 45.57 | 39.98 | 22.68 |
| Total Income | 36.93 | 58.54 | 27.66 |
| Profit After Tax | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| NET Worth | 36.47 | 30.42 | 15.06 |
| Reserves and Surplus | 30.04 | 23.98 | 9.95 |
| Total Borrowing | 4.81 | 5.05 | 2.86 |
| Amount in ₹ Crore | |||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat | 12.68 |
| 2 | Product Registration in International Markets and Product Development for sale in international markets | 2.99 |
| 3 | Funding for Marketing and Promotional Activities | 1.66 |
| 4 | To Meet Working Capital Requirements | 8.00 |
| 5 | General Corporate Purposes | 0.25 |
| Total | 25.58 |
| KPI | Oct 31, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 18.11% | 37.85% |
| ROCE | 16.68% | 33.39% |
| Debt/Equity | 0.13 | 0.17 |
| RoNW | 16.61% | 28.30% |
| PAT Margin | 16.49% | 14.77% |
| EBITDA Margin | 17.73% | 15.60% |
| Price to Book Value | 2.19 | 2.62 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 13.38 | 11.82 |
| P/E (x) | 9.27 | 10.49 |
| Promoter Holding | 59.28% | 43.44% |
| Market Cap | ₹108.94 Cr. |
The Speciality Medicines IPO is subscribed 2.27 times on March 24, 2026 6:54:39 PM (Day 3). The public issue subscribed 0.85 times in the individual investors category, 96.24 times in the QIB category, and 1.88 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (x) | Shares Offered | Shares bid for | Total Applications |
|---|---|---|---|---|
| QIB (Ex Anchor) | 96.24 | 21,000 | 20,21,000 | 0 |
| NII* | 1.88 | 10,89,000 | 20,44,000 | 0 |
| bNII (> ₹10L) | 2.50 | 7,26,000 | 18,13,000 | |
| sNII (< ₹10L) | 0.64 | 3,63,000 | 2,31,000 | |
| Individual Investor | 0.85 | 10,90,000 | 9,22,000 | 0 |
| Total | 2.27 | 22,00,000 | 49,87,000 | 688 |
Total Applications: 688
*Market Maker portion is not included to NII/HNI.
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Manager’s fees | 0.50 |
| 2 | Selling, Marketing and Underwriting Fees | 2.63 |
| 3 | Fees payable to Market Maker to the Issue | 0.06 |
| 4 | Fees payable to Registrar to the Issue | 0.02 |
| 5 | Fees payable for Advertising and Publishing expenses | 0.10 |
| 6 | Fees payable to Regulators including Stock Exchanges & Depositories | 0.10 |
| 7 | Payment for Printing & Stationery, Postage, etc. | 0.04 |
| 8 | Fees payable to Statutory Auditor, Legal Advisors and other Professionals | 0.07 |
| 9 | Others (Selling commission, ROC expenses, etc) | 0.05 |
| Total | 3.57 |
| Price Details | BSE SME |
|---|---|
| Final Issue Price | ₹124.00 |
| Open | ₹124.00 |
| Low | ₹124.00 |
| High | ₹129.50 |
| Last Trade | ₹125.90 |
Lead Manager Reports
Speciality Medicines IPO is a SME IPO of 23,50,000 equity shares of the face value of ₹10 aggregating up to ₹29 Crores. The issue is priced at ₹124 per share. The minimum order quantity is 1000.
The IPO opens on Fri, Mar 20, 2026, and closes on Tue, Mar 24, 2026.
Skyline Financial Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE SME.
Zerodha customers can apply online in Speciality Medicines IPO using UPI as a payment gateway. Zerodha customers can apply in Speciality Medicines IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Speciality Medicines IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Speciality Medicines IPO opens on Fri, Mar 20, 2026 and closes on Tue, Mar 24, 2026.
Speciality Medicines IPO lot size is 1000, and the minimum amount required for application is ₹2,48,000, with 2 lots being the minimum application size.
You can apply in Speciality Medicines IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Speciality Medicines IPO will be done on Wednesday, March 25, 2026, and the allotted shares will be credited to your demat account by Fri, Mar 27, 2026. Check the Speciality Medicines IPO allotment status.
The Speciality Medicines IPO listing date is on Mon, Mar 30, 2026.
